Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The discovery and development of antimicrobial therapies represents one of the most significant advancements in modern medicine. Although the primary therapeutic intent of antimicrobials is to eliminate their target pathogens, several antimicrobials have been shown to provide analgesia as a secondary benefit. Antimicrobials have demonstrated analgesic effects in conditions that involve dysbiosis or potential subclinical infection (e.g ., chronic low back pain with Modic type 1 changes; chronic prostatitis/chronic pelvic pain; irritable bowel syndrome; inflammatory bowel disease; functional gastrointestinal disorders/dyspepsia; myalgic encephalomyelitis/chronic fatigue syndrome), and might even prevent the chronification of pain after acute infections that are associated with excessive systemic inflammation (e.g ., post COVID-19 condition/long Covid, rheumatic fever). Clinical studies often assess the analgesic effects of antimicrobial therapies in an observational manner, without the ability to identify causative relationships, and significant gaps in the understanding remain regarding the analgesic potential of antimicrobials. Numerous interrelated patient-specific, antimicrobial-specific, and disease-specific factors altogether contribute to the perception and experience of pain, and each of these requires further study. Given worldwide concerns regarding antimicrobial resistance, antimicrobials must continue to be used judiciously and are unlikely to be repurposed as primary analgesic medications. However, when equipoise exists among several antimicrobial treatment options, the potential analgesic benefits of certain antimicrobial agents might be a valuable aspect to consider in clinical decision-making. This article (the second in a two-part series) aims to comprehensively review the evidence on the prevention and treatment of chronic pain using antimicrobial therapies and suggest a framework for future studies on this topic.
Abstract
The discovery and development of antimicrobial therapies represents one of the most significant advancements in modern medicine. Although the primary therapeutic intent of antimicrobials is to eliminate their target pathogens, several antimicrobials have been shown to provide analgesia as a secondary benefit. Antimicrobials have demonstrated analgesic effects in conditions that involve dysbiosis or potential subclinical infection (e.g ., chronic low back pain with Modic type 1 changes; chronic prostatitis/chronic pelvic pain; irritable bowel syndrome; inflammatory bowel disease; functional gastrointestinal disorders/dyspepsia; myalgic encephalomyelitis/chronic fatigue syndrome), and might even prevent the chronification of pain after acute infections that are associated with excessive systemic inflammation (e.g ., post COVID-19 condition/long Covid, rheumatic fever). Clinical studies often assess the analgesic effects of antimicrobial therapies in an observational manner, without the ability to identify causative relationships, and significant gaps in the understanding remain regarding the analgesic potential of antimicrobials. Numerous interrelated patient-specific, antimicrobial-specific, and disease-specific factors altogether contribute to the perception and experience of pain, and each of these requires further study. Given worldwide concerns regarding antimicrobial resistance, antimicrobials must continue to be used judiciously and are unlikely to be repurposed as primary analgesic medications. However, when equipoise exists among several antimicrobial treatment options, the potential analgesic benefits of certain antimicrobial agents might be a valuable aspect to consider in clinical decision-making. This article (the second in a two-part series) aims to comprehensively review the evidence on the prevention and treatment of chronic pain using antimicrobial therapies and suggest a framework for future studies on this topic.
참고문헌 (90)
- Hyson JM Jr, "A history of arsenic in dentistry", J Calif Dent Assoc, 35, pp.135~139 (2007)
- Zhao M, "Mercury and mercurycontaining preparations : history of use, clinical applications, pharmacology, toxicology, and pharmacokinetics in traditional Chinese medicine", Front Pharmacol, 13, pp.807807~ (2022)
- Parapia LA, "History of bloodletting by phlebotomy", Br J Haematol, 143, pp.490~495 (2008)
- Sun L, "Neuropathology of drug addictions and substance misuse", pp.482~489 (2016), Academic Press
- Ji-Hee Yeo, "Rapamycin reduces orofacial nociceptive responses and microglial p38 mitogen-activated protein kinase phosphorylation in trigeminal nucleus caudalis in mouse orofacial formalin model", The Korean Journal of Physiology & Pharmacology, 25(4), pp.365~374 (2021), 대한약리학회[DOI]
- Feng T, "Rapamycin ameliorates neuropathic pain by activating autophagy and inhibiting interleukin-1β in the rat spinal cord", J Huazhong Univ Sci Technolog Med Sci, 34, pp.830~837 (2014)
- Ahmed MS, "Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain", Proc Natl Acad Sci U S A, 118, pp.e2016265118~ (2021)
- Chen WF, "The use of the antimicrobial peptide piscidin(PCD)-1 as a novel anti-nociceptive agent", Biomaterials, 53, pp.1~11 (2015)
- Chang DJ, "Dapsone in rheumatoid arthritis", Semin Arthritis Rheum, 25, pp.390~403 (1996)
- Hajhashemi V, "Antiallodynia and antihyperalgesia effects of ceftriaxone in treatment of chronic neuropathic pain in rats", Acta Neuropsychiatr, 25, pp.27~32 (2013)
- Abdelaziz DM, "Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin", Breast Cancer Res Treat, 143, pp.227~237 (2014)
- Albert HB, "Antibiotic treatment in patients with chronic low back pain and vertebral bone edema(Modic type 1changes) : a double-blind randomized clinical controlled trial of efficacy", Eur Spine J, 22, pp.697~707 (2013)
- Bråten LCH, "Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study):double blind, randomised, placebo controlled, multicentre trial", BMJ, 367, pp.l5654~ (2019)
- Haight ES, "Of mice, microglia, and(wo)men : a case series and mechanistic investigation of hydroxychloroquine for complex regional pain syndrome", Pain Rep, 5, pp.e841~ (2020)
- Zhou YQ, "Minocycline as a promising therapeutic strategy for chronic pain", Pharmacol Res, 134, pp.305~310 (2018)
- Cohen JI, "Clinical practice : herpes zoster", N Engl J Med, 369, pp.255~263 (2013)
- Devor M, "Rethinking the causes of pain in herpes zoster and postherpetic neuralgia : the ectopic pacemaker hypothesis", Pain Rep, 3, pp.e702~ (2018)
- Sauerbrei A, "Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections", Eur J Clin Microbiol Infect Dis, 35, pp.723~734 (2016)
- Chen N, "Antiviral treatment for preventing postherpetic neuralgia", Cochrane Database Syst Rev, 2, pp.CD006866~ (2014)
- Huff JC, "Therapy of herpes zoster with oral acyclovir", Am J Med, 85, pp.84~89 (1988)
- Harding SP, "Oral acyclovir in herpes zoster ophthalmicus", Curr Eye Res, 10(Suppl), pp.177~182 (1991)
- Wood MJ, "A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster", N Engl J Med, 330, pp.896~900 (1994)
- Whitley RJ, "Acyclovir with and without prednisone for the treatment of herpes zoster A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group", Ann Intern Med, 125, pp.376~383 (1996)
- Wood MJ, "Efficacy of oral acyclovir treatment of acute herpes zoster", Am J Med, 85, pp.79~83 (1988)
- Morton P, "Oral acyclovir in the treatment of herpes zoster in general practice", N Z Med J, 102, pp.93~95 (1989)
- Li Q, "Antiviral treatment for preventing postherpetic neuralgia", Cochrane Database Syst Rev, 2, pp.CD006866~ (2009)
- O'Mahoney LL, "The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations : a systematic review and meta-analysis", EClinicalMedicine, 55, pp.101762~ (2022)[DOI]
- "Post COVID-19 condition (Long COVID)" (2022)[URL]
- "What is long COVID?" (2022)[URL]
- "COVID.gov/longcovid - Virus that causes COVID-19 can experience long-term effects from their infection" (2023)[URL]
- Perlis RH, "Prevalence and correlates of long COVID symptoms among US adults", JAMA Netw Open, 5, pp.e2238804~ (2022)
- Soares FHC, ";"Pain in the Pandemic Initiative Collaborators" Prevalence and characteristics of new-onset pain in COVID-19 survivours, a controlled study", Eur J Pain, 25, pp.1342~1354 (2021)
- "Nirmatrelvir and the risk of post-acute sequelae of COVID-19" (2022)[URL]
- Peluso MJ, "Effect of oral nirmatrelvir on long COVID symptoms : 4 cases and rationale for systematic studies", Pathog Immun, 7, pp.95~103 (2022)
- Davis HE, "Long COVID: major findings, mechanisms and recommendations", Nat Rev Microbiol, 21, pp.133~146 (2023)
- Abu Hamdh B, "A prospective cohort study assessing the relationship between long-COVID symptom incidence in COVID-19 patients and COVID-19 vaccination", Sci Rep, 13, pp.4896~ (2023)
- Taquet M, "Six-month sequelae of post-vaccination SARS-CoV-2 infection : a retrospective cohort study of 10, 024 breakthrough infections", Brain Behav Immun, 103, pp.154~162 (2022)
- Byambasuren O, "Effect of covid-19 vaccination on long covid : systematic review", BMJ Med, 2, pp.e000385~ (2023)
- Azzolini E, "Association between BNT162b2vaccination and long COVID after infections not requiring hospitalization in health care workers", JAMA, 328, pp.676~678 (2022)
- Tsuchida T, "Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID", J Med Virol, 94, pp.3416~3420 (2022)
- Karthikeyan G, "Acute rheumatic fever", Lancet, 392, pp.161~174 (2018)
- Gewitz MH, "Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association", Circulation, 131, pp.1806~1818 (2015)
- Gerber MA, "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis : a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research : endorsed by the American Academy of Pediatrics", Circulation, 119, pp.1541~1551 (2009)
- Robertson KA, "Antibiotics for the primary prevention of acute rheumatic fever : a meta-analysis", BMC Cardiovasc Disord, 5, pp.11~ (2005)
- Kumar RK, "Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association", Circulation, 142, pp.e337~e357 (2020)
- Lennon D, "Meta-analysis of trials of streptococcal throat treatment programs to prevent rheumatic fever", Pediatr Infect Dis J, 28, pp.e259~e264 (2009)
- Lennon D, "School-based prevention of acute rheumatic fever : a group randomized trial in New Zealand", Pediatr Infect Dis J, 28, pp.787~794 (2009)
- Lennon D, "First presentation acute rheumatic fever is preventable in a community setting : a school-based intervention", Pediatr Infect Dis J, 36, pp.1113~1118 (2017)
- Cohen SP, "Chronic pain and infection : mechanisms, causes, conditions, treatments, and controversies", BMJ Med, 1, pp.e000108~ (2022)
- Gilligan CJ, "Chronic low back pain, bacterial infection and treatment with antibiotics", Spine J, 21, pp.903~914 (2021)
- Anothaisintawee T, "Management of chronic prostatitis", chronic pelvic pain syndrome : a systematic review and network meta-analysis, 2011, pp.305, 78~86
- Franco JV, "Pharmacological interventions for treating chronic prostatitis", chronic pelvic pain syndrome, 2019, pp.10, CD012552~
- Drossman DA, "Rome IV-functional GI disorders : disorders of gut-brain interaction", Gastroenterology, 150, pp.1257~1261 (2016)
- Palsson OS, "Rome IV diagnostic questionnaires and tables for investigators and clinicians", Gastroenterology (2016)
- Barbara G, "The intestinal microenvironment and functional gastrointestinal disorders", Gastroenterology (2016)
- Ford AC, "Systematic review with meta-analysis : the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome", Aliment Pharmacol Ther, 48, pp.1044~1060 (2018)
- Black CJ, "Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern : systematic review and network meta-analysis", Gut, 69, pp.74~82 (2020)
- Lacy BE, "ACG clinical guideline : management of irritable bowel syndrome", Am J Gastroenterol, 116, pp.17~44 (2021)
- Lembo A, "AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea", Gastroenterology, 163, pp.137~151 (2022)
- Rosen MJ, "Inflammatory bowel disease in children and adolescents", JAMA Pediatr, 169, pp.1053~1060 (2015)
- Shaw SY, "Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease", Am J Gastroenterol, 105, pp.2687~2692 (2010)
- Gomollón F, "3rd European evidencebased consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management", J Crohns Colitis, 11, pp.3~25 (2017)
- Singh S, "AGA technical review on the management of moderate to severe ulcerative colitis", Gastroenterology, 158, pp.1465~1496 (2020)[DOI]
- Townsend CM, "Antibiotics for induction and maintenance of remission in Crohn's disease", Cochrane Database Syst Rev, 2, pp.CD012730~ (2019)
- Norton C, "Systematic review : interventions for abdominal pain management in inflammatory bowel disease", Aliment Pharmacol Ther, 46, pp.115~125 (2017)
- Castiglione F, "Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease", Aliment Pharmacol Ther, 18, pp.1107~1112 (2003)
- Oustamanolakis P, "Dyspepsia : organic versus functional", J Clin Gastroenterol, 46, pp.175~190 (2012)
- Ford AC, "Functional dyspepsia", Lancet, 396, pp.1689~1702 (2020)
- Du LJ, "Helicobacter pylori eradication therapy for functional dyspepsia : systematic review and meta-analysis", World J Gastroenterol, 22, pp.3486~3495 (2016)
- Kang SJ, "Helicobacter pylori eradication therapy for functional dyspepsia: a metaanalysis by region and H. pylori prevalence", J Clin Med, 8, pp.1324~ (2019)
- Ford AC, "Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia : updated systematic review and meta-analysis", Gut (2022)
- Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Suzuki H, "Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia?", J Gastroenterol Hepatol, 26(Suppl 3), pp.42~45 (2011)
- Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
- Carruthers BM, "Myalgic encephalomyelitis: International Consensus Criteria", J Intern Med, 270, pp.327~338 (2011)
- Bateman L, "Myalgic encephalomyelitis", chronic fatigue syndrome : essentials of diagnosis and management, 2021, pp.96, 2861~2878
- Rasa S, "Chronic viral infections in myalgic encephalomyelitis", chronic fatigue syndrome (ME, J Transl Med, pp.2018, 16[DOI]
- Wong TL, "Long COVID and myalgic encephalomyelitis", chronic fatigue syndrome(ME, Medicina (Kaunas), pp.2021, 57[DOI]
- Komaroff AL, "Insights from myalgic encephalomyelitis", chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19syndrome, 2021, pp.27, 895~906
- Komaroff AL, "Will COVID-19 lead to myalgic encephalomyelitis", chronic fatigue syndrome?, 2021, pp.7, 606824~
- König RS, "The gut microbiome in myalgic encephalomyelitis (ME)", chronic fatigue syndrome (CFS), 2022, pp.13, 628741~
- Ianiro G, "Antibiotics as deep modulators of gut microbiota : between good and evil", Gut, 65, pp.1906~1915 (2016)
- Smith ME, "Treatment of myalgic encephalomyelitis", chronic fatigue syndrome: a systematic review for a national institutes of health pathways to prevention workshop, 2015, pp.162, 841~850
- Strayer DR, "A controlled clinical trial with a specifically configured RNA drug, poly(I) poly(C12U), in chronic fatigue syndrome", Clin Infect Dis, 18(Suppl 1), pp.S88~S95 (1994)
- Strayer DR, "A doubleblind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome", PLoS One, 7, pp.e31334~ (2012)
- Montoya JG, "Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome", J Med Virol, 85, pp.2101~2109 (2013)
- Peterson PK, "A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome", Am J Med, 89, pp.554~560 (1990)
- Straus SE, "Acyclovir treatment of the chronic fatigue syndrome, Lack of efficacy in a placebocontrolled trial", N Engl J Med, 319, pp.1692~1698 (1988)
- Watt T, "Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers", J Med Virol, 84, pp.1967~1974 (2012)
- Theuretzbacher U, "The global preclinical antibacterial pipeline", Nat Rev Microbiol, 18, pp.275~285 (2020)